Jesús M Salvador Lab Centro Nacional de Biotecnología (CNB)

T cell activation and differentiation in tumor suppression and autoimmunity

Home

Jesús M Salvador received solid predoctoral training in protein biochemistry at the Universities of Maryland, Leeds, Catholic Univ. of Leuven, Institut Curie and Extremadura from 1994-1998. His studies were useful for understanding Ca2+ regulation in synaptosomal function. In 1999, he joined Dr. Fornace’s lab at the National Institutes of Health, Bethesda, MD, as a Postdoctoral Visiting Fellow. His major focus was to study the role of the p53 effector gene Gadd45a in T cell function. He found that Gadd45a is a negative regulator of T cell proliferation with a key role as suppressor of autoimmune disease. He developed and characterized several lines of Gadd45 knockout mice to study the DNA repair, carcinogenesis and in vivo immune responses. In 2004, he obtained a Research Fellow appointment at the NIH. He identified a novel regulatory site (Tyr323) in p38, whose phosphorylation activates p38 by a MAPKK-independent mechanism. These findings established a specific new target for experimental therapeutics in autoimmune diseases and cancer (patent WO2005/077983).

In 2005, he joined the Dept. of Immunology & Oncology at the Centro Nacional de Biotecnología, (CNB/CSIC) as Group Leader, Ramón & Cajal Investigator. Since then, Salvador´s group is dissecting the biochemical pathways leading to development of autoimmunity and cancer in the Gadd45 and p38 MAPK murine models. They are studying the role of the alternative p38 pathway in T cell activation, differentiation and their regulation through the Gadd45 family. His group has found evidences that the alternative pathway is relevant in autoimmunity development and has identified a novel prognostic marker of rheumatoid arthritis (Patent P200702770). In 2008, he obtained an Associate Professor appointment (permanent position) at CNB-CSIC. He has received awards for outstanding research in biomedical sciences, including ERC (European Research Council) starting grant 2008, the Fundación Hospital de Madrid Award 2006, the I Biogen Idec Young Investigator Award 2005, the NIH Fellows Award for Research Excellence (FARE) in 2003 and 2005 and was selected by the European Science Foundation as a EURYI (European Young Investigator Award) finalist in Biomedicine 2007.

PRINCIPAL INVESTIGATOR

Jesús M Salvador

Jesús M Salvador